Antares Pharma (ATRS) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free atrs Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAntares Vision SpA AVmorningstar.com - January 24 at 12:23 AMAntares Vision Share Price (AV.MI)lse.co.uk - December 7 at 7:11 PMAprea Therapeutics’ Promising Clinical Data and Distinctive Drug Profile: An Analysis of Jason McCarthy’s Buy Ratingmarkets.businessinsider.com - October 19 at 10:34 AMAntares Reaches New 52-Week High (AIS)thestreet.com - September 3 at 2:09 AMAntares Vision SpA (ANV)investing.com - August 2 at 6:59 AMCOP Syringes Market Competitive Situation By 2030marketwatch.com - April 27 at 12:48 PMPharma Track and Trace Solutions Market Trends By 2031marketwatch.com - April 6 at 8:56 AMTransdermal Patch Drug Delivery System Market Size, Share, Demand, Opportunity, Outlook, Trends, Revenue, and Future Growth 2027marketwatch.com - March 28 at 3:07 PMDrug Transport Technology Market Top Players By 2031marketwatch.com - March 27 at 12:48 AMDrug Delivery Technology Market 2023 Size and Forecast to 2030marketwatch.com - March 25 at 12:28 AMPharma Track and Trace Solutions Market Forecast 2023 To 2029 Size, Global Predictive Analyticsmarketwatch.com - March 4 at 2:21 AMGlobal Genitourinary Drugs Market Report 2022 to 2027: Featuring Allergan, Antares Pharma, Bayer and Novartis Among Othersyahoo.com - February 17 at 3:45 PMPharma Track and Trace Solutions Market : Analysis, Forecast, Size, New Trends and Insights, Update, COVID-19 Impactmarketwatch.com - January 4 at 9:39 AMPharma Track and Trace Solutions Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028marketwatch.com - December 16 at 9:18 AMDrug Delivery Technology Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2030marketwatch.com - December 1 at 5:31 PMPharmaceutical Drug Delivery Global Market Report 2022yahoo.com - September 14 at 3:29 AMPharma Track and Trace Solutions Market Report Detailed Market Analysis and Forecasts 2022 To 2028 | 112 Pages Reportmarketwatch.com - August 20 at 4:37 AMLooking Into Antares Pharma's Return On Invested Capitalmsn.com - June 8 at 3:14 PMmarketbeat.com - May 24 at 6:02 AMHalozyme: Antares Pharma Bolsters Growth Prospectsseekingalpha.com - May 19 at 5:43 AMMiMedx Group and Inozyme Stock See Action From Activist Investorsfinance.yahoo.com - May 6 at 6:11 PMHALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMAfinance.yahoo.com - April 26 at 10:31 AMLooking Into Antares Pharma Inc's Recent Short Interestbenzinga.com - April 14 at 9:50 AMAntares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?finance.yahoo.com - April 14 at 9:50 AMAntares Pharma to be acquired by Halozyme in $960M dealfinance.yahoo.com - April 13 at 3:30 PMWhy Is Antares Pharma (ATRS) Stock Up Today?investorplace.com - April 13 at 11:06 AMAntares Pharma stock rockets after Halozyme buyout deal for a near-50% premiummorningstar.com - April 13 at 10:30 AMWhy Antares Pharma Stock Is Bolting Higher Todayfool.com - April 13 at 8:33 AMAntares Pharma Announces FDA Approval Of TLANDO(TM), an Oral Treatment for Testosterone Replacement Therapystockhouse.com - March 29 at 9:29 AMThe Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebiamsn.com - March 29 at 9:29 AMAntares wins full FDA approval for testosterone replacement therapyseekingalpha.com - March 29 at 9:29 AMAntares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapyfinance.yahoo.com - March 29 at 9:29 AMAntares Pharma's Return On Capital Employed Overviewbenzinga.com - March 8 at 3:02 PMAntares Pharma (ATRS) Investor Presentation - Slideshowseekingalpha.com - March 8 at 1:39 PMZacks Investment Research Upgrades Antares Pharma (NASDAQ:ATRS) to Holdmarketbeat.com - March 7 at 5:32 PMAntares Pharma: Q4 Earnings Snapshotapnews.com - March 3 at 10:10 AMAntares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Resultsfinance.yahoo.com - March 3 at 10:10 AMAntares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimatesfinance.yahoo.com - March 3 at 10:10 AMSmileDirectClub (SDC) Reports Q4 Loss, Lags Revenue Estimatesfinance.yahoo.com - February 28 at 8:27 PMAntares Pharma to Present at the Cowen 42nd Annual Healthcare Conferencefinance.yahoo.com - February 28 at 12:15 PMAntares Pharma (NASDAQ:ATRS) Could Easily Take On More Debtfinance.yahoo.com - February 18 at 7:35 AMHenry Schein (HSIC) Q4 Earnings and Revenues Beat Estimatesfinance.yahoo.com - February 15 at 10:57 AMHere's Why I Think Antares Pharma (NASDAQ:ATRS) Might Deserve Your Attention Todaynasdaq.com - January 13 at 8:32 AMAntares Pharma, Inc.'s (NASDAQ:ATRS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?finance.yahoo.com - January 13 at 8:32 AMAntares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resourcesfinance.yahoo.com - January 12 at 12:21 PMAntares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescuefinance.yahoo.com - January 11 at 9:06 AMMedMira strengthen its Board with New Appointmentfinance.yahoo.com - December 17 at 8:58 AMAssertio Shares Gain After Buying Antares' Rheumatoid Arthritis Treatment For $44Mmarkets.businessinsider.com - December 16 at 9:29 AMIf You Like EPS Growth Then Check Out Antares Pharma (NASDAQ:ATRS) Before It's Too Latefinance.yahoo.com - December 8 at 8:29 AMLPCN: Antares Agreement & NASH Fast Track Change the Calculusfinance.yahoo.com - November 8 at 3:50 PM Get Antares Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 ATRS Media Mentions By Week ATRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRS News Sentiment▼0.000.32▲Average Medical News Sentiment ATRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRS Articles This Week▼00▲ATRS Articles Average Week Get Antares Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATRI News OSUR News ANIK News CERS News UTMD News ARAY News CTSO News ICUI News MDXG News AORT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antares Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
